Bluebird Bio Has Entered Into An Agreement To Sell A Rare Pediatric Disease Priority Review Voucher (PRV), If Received, In Connection With The Potential Approval Of Lovotibeglogene Autotemcel (Lovo-cel) For Sickle Cell Disease

bluebird bio, Inc. +16.80% Pre

bluebird bio, Inc.





0.00% Pre

Under the terms of the agreement, rights to the PRV will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is contingent upon the FDA’s approval of the biologics license application (BLA) for lovo-cel and granting of the PRV.


Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via